ArticleJournal of clinical medicine2021
Fecal Microbiota Transplant in Severe and Non-Severe
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- Research progress on the microbiota-gut-brain axis in autism spectrum disorder: a narrative review.Frontiers in microbiology · 2026Review
- Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study.Alimentary pharmacology & therapeutics · 2026Article
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Factors for Treatment Failure After Fecal Microbiota Transplantation inMicroorganisms · 2024Article
- The Role of Microbiome and Probiotics in Chemo-Radiotherapy-Induced Diarrhea: A Narrative Review of the Current Evidence.Cancer reports (Hoboken, N.J.) · 2024Review
- The Interaction between Stress and Inflammatory Bowel Disease in Pediatric and Adult Patients.Journal of clinical medicine · 2024Review
- A Real-World Study on the Clinical Characteristics, Outcomes, and Relationship between Antibiotic Exposure andAntibiotics (Basel, Switzerland) · 2024Article
- Fecal microbiota transplantation in a patient with chronic diarrhea and primary and secondary immunodeficiency (common variable immunodeficiency and splenectomy).Frontiers in cellular and infection microbiology · 2024Article
- Review
- A Simple In Vitro Test to Select Stools for Fecal Microbiota Transplantation to Limit Intestinal Carriage of Extensively Drug-Resistant Bacteria.Microorganisms · 2023Article
- A Pharmacovigilance Study Regarding the Risk of Antibiotic-AssociatedPharmaceuticals (Basel, Switzerland) · 2023Article
- Fecal Microbiota Transplantation in Liver Cirrhosis.Biomedicines · 2023Review
- Therapeutic Perspectives for Microbiota Transplantation in Digestive Diseases and Neoplasia-A Literature Review.Pathogens (Basel, Switzerland) · 2023Review
- Fecal Microbiota Transplantation in Inflammatory Bowel Disease.Biomedicines · 2023Review
- Fecal microbiota transplantation as potential first-line treatment for patients withWorld journal of gastrointestinal surgery · 2023Article
- Controversies in the Prevention and Treatment ofMicroorganisms · 2023Review
- Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 andBiomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundFaecal microbiota transplant (FMT) is a highly effective therapy for recurrent
methodsWe conducted a retrospective study to analyze the clinical characteristics and the outcomes of 96 FMT patients with a prior 10 day course of antibiotic treatment in the medical records, of which 71 patients with recurrent CDI and 25 patients with a primary CDI.
resultsThe overall primary cure rate in our study was 88.5% and the primary cure rate for the severe forms was 85.7%. The data analysis revealed 5.25%, 15.15%, and 27.3% FMT recurrence rates for primary, secondary, and tertiary severe CDI. The risk of recurrence was significantly associated with FMT after the second and the third CDI severe episodes (
conclusionsThis study brings new data in supporting the FMT role in CDI treatment, including the primary severe CDI, however, further prospective and controlled studies on larger cohorts should be performed in this respect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.